Clinical trial
A Phase Ⅰ Study for Safety, Tolerance, Pharmacokinetic Characteristic of MAX-40279-01 in Patients With Advanced Solid Tumors
NCT04183764 is registered in ClinicalTrials.gov with Maxinovel Pty., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅰ Study for Safety, Tolerance, Pharmacokinetic Characteristic of MAX-40279-01 in Patients With Advanced Solid Tumors
- Lead sponsor
- Maxinovel Pty., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- November 28, 2019
- Completion date
- December 1, 2022
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumor